MediPharm Labs Corp.

In terms of your plan of action with the change in Germany, that'd be appreciated. Thank you.

Hey, Aaron. Thanks for the question. It's Dave. I'll let Keith, our German expert, take this one. There's lots of questions there and there's lots of good opportunities in Germany. Keith, go ahead.

Thanks, Aaron. We're really excited about the legislation change. It's a little bit faster even than we expected. We thought that the federal representatives might have sent it back for further comment. So we're really happy with where things are at now, and we're really excited about what it can do. I think for us, it's the removal of that narcotics license. So as you know, the legalization itself is based around more personal possession and personal cultivation to start. That's what they're calling Tier 1, and Tier 2 hopefully will be somewhat of a commercial program. But by removing the narcotics license, it allows us to flow goods easier, allows our pharmacy partners to store goods easier. And even places like in our distribution channel where there's special storage requirements and things like that. So I think that there's a really good opportunity there to see additional growth. You asked a little bit about where our business is in Germany and how it's broken up. Our main partner there remains to be Stata. And Stata is a large European generic and wellness-focused company. Right now, they're doing great in the oil category. So when it comes to flour, there are a lot of patients that are looking to, that are more discerning customers and looking for the next hottest, coolest flour. And what that is really focused on is the medical patient. And those medical patients are using that oil product. And they are number two in that category in Germany today. And it continues to grow. With the acquisition of Vivo, we did pick up the Beacon Health GMBH, which has its own suite of licenses for import, manufacturing, and distribution. We use that to strengthen our back end, and we do have a few SKUs that we do distribute under that Beacon brand, but it's not a large piece of our business today. It's something that we look to grow in the future. And then lastly, I'll just touch on geranabinol. As you mentioned, geranabinol is a THC isolate And it's used as a compounding product. And traditionally, a lot of the production has been done synthetically. And that synthetic chemical production is very high cost. And so what we are able to do is we're able to do a natural process here at our factory in Barrie under GMP pharmaceutical conditions. And we can make that at a larger scale and arguably also at a more competitive price. And we have started selling that in the market in Q4. And in Q1, sales have picked up drastically for that product. It's not something that's distributed by Stata. It's really used as like an API and a compounding from specialty pharmacy. So Stata themselves are more focused on their brand. So they have the Canada Stata brand and they continue to grow that brand. And so the generic product, we do through a number of other distributors and it's more of a distributor pharmacist relationship for that actual product.